Addressing the labiomental crease February 12, 2017 By Lisette Hilton According to Dr. Sheila Barbarino, filling the deep groove below the lip goes a long way in the overall result for facial rejuvenation. The Microdroplet Lift February 12, 2017 By Lisette Hilton Dr. Kenneth Steinsapir reveals his patented botulinum toxin delivery method that minimizes brow activity without treating the forehead. Beyond ACOs Alternative payment models of the future Why today’s models will always be interim ones—and
how the consumerization of healthcare will drive change. Botox, Dysport, Xeomin not interchangeable May 31, 2016 By Lisette Hilton Study shows “accepted” equivalents of neurotoxin treatment dosages do not deliver comparable results. Injectable treatment for reducing abdominal fat? May 31, 2016 It’s called Lipo 202 and offers potential benefits, including revision liposuction. Three drug trends impacting specialty pharmacy April 21, 2016 By Mari Edlin AMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching Nuances of Asian aesthetics March 08, 2016 By Lisette Hilton It’s the fastest growing ethnic group in the U.S. and one that requires you approach cosmetic treatment with an eye to facial harmony, not rejuvenation. Neurotoxin pipeline advances, stay wary of counterfeits January 28, 2016 By Cheryl Guttman As the neurotoxin market is set for expansion, so expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeits. What will be the industry game changers in 2016? December 17, 2015 By Lisette Hilton What do your colleagues predict will be the specialty’s game-changers in 2016? Here is what some said they are most looking forward to in the coming year. Botox + Dysport: Better together? November 03, 2015 By Lisette Hilton One doctor says using a combination of Botox and Dysport creates a better result than using either one alone.